Triglycerides and the risk of coronary heart disease: 10 158 Incident cases among 262 525 participants in 29 Western prospective studies

Circulation

Volumn 115, Issue 4, 2007, Pages 450-458

  Sarwar, Nadeem ^a   Danesh, John ^a,f   Eiriksdottir, Gudny ^d   Sigurdsson, Gunnar ^d   Wareham, Nick ^b   Bingham, Sheila ^c   Boekholdt, S Matthijs ^e   Khaw, Kay Tee ^a   Gudnason, Vilmundur ^d  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b MRC EPIDEMIOLOGY UNIT   (United Kingdom)

^c MRC Centre for Nutritional Epidemiology in Cancer Prevention and Survival   (United Kingdom)

^d ICELANDIC HEART ASSOCIATION   (Iceland)

^e ACADEMIC MEDICAL CENTER   (Netherlands)

^f UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Coronary disease; Epidemiology; Lipids; Meta analysis; Triglycerides

Indexed keywords

CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; BLOOD PRESSURE; CHOLESTEROL BLOOD LEVEL; COHORT ANALYSIS; CONTROLLED STUDY; CORRELATION COEFFICIENT; FEMALE; HUMAN; INCIDENCE; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK FACTOR;

CASE-CONTROL STUDIES; CORONARY DISEASE; HUMANS; INCIDENCE; PROSPECTIVE STUDIES; RISK FACTORS; TRIGLYCERIDES;

EID: 33846637379     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.106.637793     Document Type: Article

References (46)

1. Packard C, Saito Y. Non-HDL cholesterol as a measure of atherosclerotic risk. J Atheroscler Thromb. 2004;11:6-14.
2. Sharrett A, Ballantyne C, Coady M, Heiss G, Sorlie P, Catellier D, Patsch W. Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein (a), apolipoproteins A-I and B, and HDL density subfractions. Circulation. 2001;104:1108-1113.
3. Wilson P, Larson M, Castelli W. Triglycerides, HDL-cholesterol and coronary artery disease: a Framingham update on their interrelations. Can J Cardiol. 1994;10:5B-9B.
4. Stenswold I, Tverdal A, Urdal P, Graff-Iversen S. Non fasting serum triglyceride concentration and mortality from coronary heart disease and any cause in middle aged Norwegian women. BMJ. 1993;307:1318-1322.
5. Tuerdal A, Foss O, Leren P, Holme I, Lund-Larsen P, Bjartveir K. Serum triglycerides as an independent risk factor for death from coronary heart disease in middle aged Norwegian men. Am J Epidemiol. 1989;129:458-465.
6. Stanvenow L, Kjellstrom T. Influence of serum triglyceride levels on the risk for myocardial infarction in 12 510 middle aged males: interaction with serum cholesterol. Atherosclerosis. 1999;147:243-247.
7. Psaty BM, Anderson M, Kronmal RA, Tracy RP, Orchard T, Fried LP, Lumley T, Robbins J, Burke G, Newman AB, Furberg CD. The association between lipid levels and the risk of incident myocardial infarction, stroke, and total mortality: the Cardiovascular Health Study. J Am Geriatr Soc. 2004;52:1639-1647.
8. Alvins AL, Newhaus JM. Do triglycerides provide meaningful information about heart disease risk? Arch Intern Med. 2000;160:1937-1944.
9. Pocock S, Shaper AG, Phillips AN. Concentrations of high density lipoprotein cholesterol, triglycerides and total cholesterol in ischaemic heart disease. BMJ. 1989;298:998-1002.
10. Bottiger Le, Carlson LA. Risk factors for death for males and females. Acta Med Scand. 1982;211:437-442.
11. Stampfer MJ, Krauss RM, Ma J, Blanche PJ, Hoil LG, Sacks FM, Hennekens CH. A prospective study of triglyceride level, low-density lipoprotein particle diameter, and risk of myocardial infarction. JAMA. 1996;276:882-888.
12. Rosenman R, Brand R, Jenkins D, Friedman M, Straus R, Wurm M. Coronary heart disease in the Western Collaborative Group Study. JAMA. 1975;233:872-877.
13. Shai I, Rimm EB, Hankinson SE, Curhan G, Manson JE, Rifai N, Stampfer MJ, Ma J. Multivariate assessment of lipid parameters as predictors of coronary heart disease among post menopausal women. Circulation. 2004;110:2824-2830.
14. Jeppesen J, Hein H, Suadicani P, Gyntelberg F. Triglyceride concentration and ischemic heart disease: an eight-year follow-up in the Copenhagen Male Study. Circulation. 1998;97:1029-1036.
15. Salonen J, Puska P. Relation of serum cholesterol and triglycerides to the risk of acute myocardial infarction, cerebral stroke and death in eastern Finnish male population. Int J Epidemiol. 1983;12:26-31.
16. Criqui M, Heiss G, Cohn R, Cowan LD, Suchindran CM, Bangdiwala S, Kritchevsky S, Jacobs DR Jr, O'Grady HK, Davis CE. Plasma triglyceride levels and mortality from coronary heart disease. N Engl J Med. 1993;328:1220-1225.
17. Assmann G, Schulte H. Relation of HDL cholesterol and triglycerides to incidence of atherosclerotic coronary artery disease (the PROCAM experience). Am J Cardiol. 1992;70:733-737.
18. Talmud P, Hawe E, Miller G, Humphries S. Non-fasting apolipoprotein B and triglyceride levels as useful predictor of coronary heart disease risk in middle-aged UK men. Arterioscler Thromb Vasc Biol. 2002;22:1918-1923.
19. Cambien F, Jacqueson A, Richard J, Warmet J, Ducimetiere P, Claude J. Is the level of serum triglyceride a significant predictor of coronary death in "normocholesterolemic" subjects? Am J Epidemiol. 1986;124:624-632.
20. Bainton D, Miller N, Bolton C, Yarnell J, Sweetnam P, Baker I, Lewis B, Elwood P. Plasma triglyceride and HDL cholesterol as predictors of ischaemic heart disease in British men. Br Heart J. 1992;68:60-66.
21. Austin M, Rodriguez B, McKnight B, Mcneely M, Edwards K, Curb D, Sharp D. Low density lipoprotein particle size, triglycerides, and high density lipoprotein cholesterol as risk factors for coronary heart disease in older Japanese American Men. Am J Cardiol. 2000;86:412-16.
22. Menotti A, Scanga M, Morisi G. Serum triglycerides in the prediction of coronary artery disease (an Italian experience). Am J Cardiol. 1994;73:29-32.
23. Aberg H, Lithell H, Serlinus I, Hedstrand H. Serum triglycerides as a risk factor for myocardial infarction but not for angina pectoris. Atherosclerosis. 1985;54:89-97.
24. Pelkonen R, Nikkila E, Koskinen S, Penttinen K, Sarna S. Association of serum lipids and obesity with cardiovascular mortality. BMJ. 1977;2:1185-1187.
25. Heyden S, Heiss G, Hames, Bartel AG. Fasting triglycerides as predictors of total and CHD mortality in Evans County, Georgia. J Chron Dis. 1980;33:275-282.
26. Wilhelmsen L, Wedel H, Tibslin G. Multivariate analysis of risk factors for coronary heart disease. Circulation. 1973;48:950-958.
27. Glynn R, Rosner B, Silbert J. Changes in cholesterol and triglycerides as predictors of ischaemic heart disease in men. Circulation. 1982;4:724-731.
28. Bengtsson C, Bjorkelund C, Lapidus L, Lissmen L. Associations of serum lipid concentrations and obesity with mortality in women: 20 year follow up of participants in prospective population study in Gothenburg, Sweden. BMJ. 1993;307:1385-1388.
29. Hokanson JE, Austin MA. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J Cardiovasc Risk. 1996;3:213-219.
30. Asia Pacific Cohort Studies Collaboration. Serum triglycerides as a risk factor for cardiovascular diseases in the Asia-Pacific region. Circulation. 2004;110:2678-2686.
31. Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Cholesterol in Adults (Adult Treatment Panel III): final report. Circulation. 2002;106:3143-3421.
32. Jonsdottir S, Sigfusson N, Gudnason V, Sigvaldson H, Thorgeirsson G. Do lipids, blood pressure, diabetes and smoking confer equal risk of myocardial infarction in women as in men? The Reykjavik Study. J Cardiovasc Risk. 2002;9:67-76.
33. Day N, Oakes S, Luben R, Khaw KT, Bingham S, Welch A, Wareham N. EPIC-Norfolk study design and characteristics of the cohort: European Prospective Investigation of Cancer. Br J Cancer. 1999;80:95-103.
34. Clarke R, Shipley M, Lewington S. Underestimation of risk associations due to regression dilution in long-term follow-up of prospective studies. Am J Epidemiol. 1999;150:341-353.
35. Danesh J, Collins R, Appleby P, Peto R. Association of fibrinogen, C-reactive protein, albumin or leukocyte count with coronary heart disease: meta-analysis of prospective studies. JAMA. 1998;279:1477-1482.
36. Higgins J, Thompson S, Deeks J, Altman D. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557-560.
37. Wilsgaard T, Jacobsen BK, Schirmer H, Thune I, Lochen ML, Njolstad I, Arnesen E. Tracking of cardiovascular risk factors: the Tromso study, 1979-1995. Am J Epidemiol. 2001;154:418-426.
38. Brown D, Kinch S, Doyle J. Serum triglycerides in health and in ischemic heart disease. N Engl J Med. 1965;273:947-952.
39. Eckel R, Grundy S, Zimmet P. The metabolic syndrome. Lancet. 2005;365:1415-1428.
40. Rubins HB, Robins SJ, Collins D, Fye CL, Anderson JW, Elam MB, Faas FH, Linares E, Schaefer EJ, Schectman G, Wilt TJ, Wittes J, for the Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Engl J Med. 1999;341:410-418.
41. Diabetes Atherosclerosis Intervention Study Investigators. Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study. Lancet. 2001;357:905-910.
42. Field Study Investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study); randomised controlled trial. Lancet. 2005;366:1849-1861.
43. Meade T. Design and intermediate results of the Lower Extremity Arterial Disease Event Reduction (LEADER) trial of bezafibrate in men with lower extremity arterial disease. Curr Control Trials Cardiovasc Med. 2001;2:195-204.
44. Davey Smith G, Ebrahim S. What can mendelian randomization tell us about modifiable behavioural and environmental exposures? BMJ. 2005;330:1076-1079.
45. Lee KWJ, Ayyobi AF, Frohlich JJ, Hill JS. APOA5 gene polymorphism modulates levels of triglyceride, HDL cholesterol and FERHDL but is not a risk factor for coronary artery disease. Atherosclerosis. 2004;176:165-172.
46. Lai CQ, Demissie S, Cupples LA, Zhu Y, Adiconis X, Parnell LD, Corella D, Orduvas JM. Influence of the APOA5 locus on plasma triglyceride, lipoprotein subclasses, and CVD risk in the Framingham Heart Study. J Lipid Res. 2004;45:2096-2105.